Abstract
Bisphosphonates (BPs) and similarly acting bone antiresorptive agents such as denosumab are becoming the principal if not sole therapeutic agents for the preventative treatment against fracture occurrence in osteoporosis (OP) patients. BPs are also increasingly used in the treatment of severely painful and potentially life-shortening bone complications, including fracture occurrence, in cancer patients. Are we seeing not only a rapid expansion of research focused on the prevention and treatment of osteonecrosis of the jaw (ONJ) but also the emergence of a new sub-specialty focusing on the diagnosis, prevention and treatment of ONJ?
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
